Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response
We here show that response and toxicity to cICB in advanced melanoma are driven by distinct immune features evident after only one cycle of treatment. These could serve as prognostic biomarkers upon validation in larger cohorts.
Authors
- Jack Edwards (ORCID: https://orcid.org/0000-0002-8416-009X)
- Miles C. Andrews (ORCID: https://orcid.org/0000-0003-1231-8641)
- Sashendra Senthi
- Hayley Burridge
- Mark Shackleton (ORCID: https://orcid.org/0000-0002-7673-4655)
- Menno C. van Zelm (ORCID: https://orcid.org/0000-0003-4161-1919)
- Robin B. Smith
- Carole Owens
Institutions
- Erasmus MC (NL)
- The Alfred Hospital (AU)
- Alfred Health (AU)
- Monash University (AU)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012317
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government
- Equity Trustees
- Tour de Cure
- Medical Research Council